Ranibizumab News and Research

RSS
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

Choroidal consequences differ between anti-VEGF therapies

Choroidal consequences differ between anti-VEGF therapies

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Ranibizumab trial gets promising results for CNV

Ranibizumab trial gets promising results for CNV

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

No added benefit from aflibercept, shows study

No added benefit from aflibercept, shows study

Promising technique for treating eye disease proves effective in preclinical studies

Promising technique for treating eye disease proves effective in preclinical studies

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Eylea can ease vision problems for wet AMD patients

Eylea can ease vision problems for wet AMD patients

Aflibercept drug used for AMD shows no added benefit over current standard therapy

Aflibercept drug used for AMD shows no added benefit over current standard therapy

New study suggests that Ranibizumab can be potential prophylaxis for PVR

New study suggests that Ranibizumab can be potential prophylaxis for PVR

AACR recognizes scientists whose contributions to cancer field have extraordinary impact

AACR recognizes scientists whose contributions to cancer field have extraordinary impact

Antibiotic prophylaxis after IVT may be harmful

Antibiotic prophylaxis after IVT may be harmful